Best pharma stocks in 2026: ranked by real data
Every listed company in the Medicine, pharma & life science value chain (53 stocks), mechanically ranked by actual market data. No opinions, no January listicle. Re-ranked every trading day.
As of August 26, 2026, the strongest pharma stock this year is Moderna (MRNA, +371.0% YTD), while Eli Lilly leads on size at $1.2T. Unlike a listicle written in January, this page re-ranks itself every trading day from real market data.
Top 10 by return this year
Total return YTD, prices adjusted for splits and dividends.
| # | Company | YTD return | 1Y return | Market cap |
|---|---|---|---|---|
| 1 | ModernaMRNABiotech & innovation | +371.0% | +412.1% | $25.2B |
| 2 | IlluminaILMNLife science tools | +70.2% | +119.3% | $28.7B |
| 3 | Charles River LaboratoriesCRLCDMO & pharma manufacturing | +49.7% | +84.5% | $13.6B |
| 4 | Merck & Co.MRKBig pharma | +43.1% | +72.4% | $330B |
| 5 | NateraNTRADiagnostics | +43.1% | +97.9% | $44.6B |
| 6 | Quest DiagnosticsDGXDiagnostics | +40.5% | +35.3% | $26.1B |
| 7 | Baxter InternationalBAXMedtech & devices | +38.6% | +7.9% | $14B |
| 8 | DexComDXCMDiabetes & metabolic disease | +37.2% | +10.7% | $34.5B |
| 9 | AmgenAMGNBiotech & innovation | +35.6% | +51.1% | $226B |
| 10 | LabcorpLHDiagnostics | +35.3% | +22.0% | $26.2B |
Data as of 2026-08-26 · updates daily after U.S. close
The 10 largest by market cap
The heavyweights of the pharma chain.
| # | Company | Market cap | Today | P/E |
|---|---|---|---|---|
| 1 | Eli LillyLLYDiabetes & metabolic disease | $1.2T | −1.1% | 43.2 |
| 2 | Johnson & JohnsonJNJBig pharma | $630B | +0.0% | 29.9 |
| 3 | AbbVieABBVBig pharma | $443B | +0.5% | 70.2 |
| 4 | UnitedHealthUNHDistribution & pharmacy infrastructure | $362B | −0.5% | 25.6 |
| 5 | Merck & Co.MRKBig pharma | $330B | +3.8% | 103.9 |
| 6 | AmgenAMGNBiotech & innovation | $226B | −0.4% | 25.8 |
| 7 | Thermo Fisher ScientificTMOLife science tools | $223B | −0.1% | 31.9 |
| 8 | Abbott LaboratoriesABTDiagnostics | $193B | −0.5% | 35.5 |
| 9 | Gilead SciencesGILDBiotech & innovation | $170B | +1.4% | — |
| 10 | PfizerPFEBig pharma | $152B | +2.1% | 35.2 |
Lowest valuation (P/E)
Lowest positive trailing P/E. Cheap can be cheap for a reason; see each profile for the risks.
| # | Company | P/E | P/S | Market cap |
|---|---|---|---|---|
| 1 | The Cigna GroupCIDistribution & pharmacy infrastructure | 11.5 | 0.3 | $73.9B |
| 2 | ZoetisZTSBig pharma | 11.5 | 3.2 | $30.2B |
| 3 | Bristol Myers SquibbBMYBig pharma | 14.2 | 2.7 | $132B |
| 4 | IncyteINCYBiotech & innovation | 15.1 | 4.2 | $24.4B |
| 5 | GE HealthCareGEHCMedtech & devices | 16.8 | 1.6 | $33.3B |
| 6 | United TherapeuticsUTHRBiotech & innovation | 17.0 | 7.1 | $22.3B |
| 7 | RegeneronREGNBiotech & innovation | 19.0 | 5.3 | $82.2B |
| 8 | Boston ScientificBSXMedtech & devices | 20.4 | 3.6 | $75B |
| 9 | ResMedRMDMedtech & devices | 21.5 | 5.8 | $32.7B |
| 10 | McKessonMCKDistribution & pharmacy infrastructure | 21.9 | 0.2 | $101B |
Methodology: the universe is Sectivia's curated Medicine, pharma & life science value chain: U.S.-listed companies grouped by their role in the chain. Rankings are purely mechanical from daily Finnhub data. "Best" here means best on the stated metric, not a recommendation. Companies without data for a metric are excluded from that table.
See all 53 companies on the interactive Pharma value-chain map: segments, supply-chain links and daily metrics.Open the Pharma map →